Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Fezakinumab

Catalog #:   DHJ53501 Specific References (15) DATASHEET
Host species: Human
Isotype: IgG1-lambda
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHJ53501

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG1-lambda

Clonality

Monoclonal

Target

Interleukin-22, Cytokine Zcyto18, IL-22, ZCYTO18, IL22, ILTIF, IL-TIF, IL-10-related T-cell-derived-inducible factor

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9GZX6

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

ILV-094, CAS: 1007106-86-6

Clone ID

Fezakinumab

Data Image
  • SDS-PAGE
    SDS PAGE for Fezakinumab
  • Bioactivity
    Detects Human IL22 in indirect ELISAs.
References

A Double Edged Sword Role of Interleukin-22 in Wound Healing and Tissue Regeneration, PMID: 33042126

A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis, PMID: 33894014

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab, PMID: 30121291

Biological therapies for atopic dermatitis: An update, PMID: 30679974

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial, PMID: 29353025

Efficacy of biologics in atopic dermatitis, PMID: 32003247

Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma, PMID: 33891981

New therapies for atopic dermatitis: Additional treatment classes, PMID: 29248520

Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018, PMID: 30095475

Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis, PMID: 34213742

Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis, PMID: 32525769

Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis, PMID: 32507066

Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution, PMID: 29659645

The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis, PMID: 30319661

What's New in Atopic Dermatitis, PMID: 30850043

Datasheet

Document Download

Research Grade Fezakinumab.pdf

 

$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Fezakinumab [DHJ53501]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only